Sage Therapeutics (STU:SG7) Cash And Cash Equivalents : €41.83 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cash And Cash Equivalents?

Sage Therapeutics's quarterly cash and cash equivalents declined from Sep. 2024 (€89.76 Mil) to Dec. 2024 (€77.38 Mil) but then stayed the same from Dec. 2024 (€77.38 Mil) to Mar. 2025 (€41.83 Mil).

Sage Therapeutics's annual cash and cash equivalents declined from Dec. 2022 (€153.59 Mil) to Dec. 2023 (€65.10 Mil) but then increased from Dec. 2023 (€65.10 Mil) to Dec. 2024 (€77.38 Mil).

Sage Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Sage Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cash And Cash Equivalents Chart

Sage Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,365.41

260.40

153.59

65.10

77.38

Sage Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															158.84	92.81	89.76	77.38	41.83

Sage Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sage Therapeutics (STU:SG7) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sage Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

55 Cambridge Parkway, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Headlines

No Headlines